These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33586712)

  • 1. Ultrasensitive detection of programmed death-ligand 1 (PD-L1) in whole blood using dispersible electrodes.
    Moazzam P; Myekhlai M; Alinezhad A; Alshawawreh FA; Bakthavathsalam P; Gonçales VR; Tilley RD; Gooding JJ
    Chem Commun (Camb); 2021 Mar; 57(20):2559-2562. PubMed ID: 33586712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode.
    Niedziałkowski P; Bojko M; Ryl J; Wcisło A; Spodzieja M; Magiera-Mularz K; Guzik K; Dubin G; Holak TA; Ossowski T; Rodziewicz-Motowidło S
    Bioelectrochemistry; 2021 Jun; 139():107742. PubMed ID: 33517203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New electrochemical method for programmed death-ligand 1 detection based on a paper-based microfluidic aptasensor.
    Xing Y; Liu J; Sun S; Ming T; Wang Y; Luo J; Xiao G; Li X; Xie J; Cai X
    Bioelectrochemistry; 2021 Aug; 140():107789. PubMed ID: 33677221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasensitive electrochemical detection of prostate-specific antigen (PSA) using gold-coated magnetic nanoparticles as 'dispersible electrodes'.
    Chuah K; Lai LM; Goon IY; Parker SG; Amal R; Justin Gooding J
    Chem Commun (Camb); 2012 Apr; 48(29):3503-5. PubMed ID: 22389188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
    Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
    Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
    [No Abstract]   [Full Text] [Related]  

  • 6. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
    Amatatsu M; Arigami T; Uenosono Y; Yanagita S; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Ishigami S; Natsugoe S
    Cancer Sci; 2018 Mar; 109(3):814-820. PubMed ID: 29345842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
    Wei W; Xu B; Wang Y; Wu C; Jiang J; Wu C
    Medicine (Baltimore); 2018 Jan; 97(3):e9617. PubMed ID: 29504990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
    Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks.
    Cao Y; Wang Y; Yu X; Jiang X; Li G; Zhao J
    Biosens Bioelectron; 2020 Oct; 166():112452. PubMed ID: 32738648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
    Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
    Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic deposition of gold nanoparticles at vertically aligned carbon nanotubes for electrochemical stripping analysis and ultrasensitive immunosensing of carcinoembryonic antigen.
    Deng L; Lai G; Fu L; Lin CT; Yu A
    Analyst; 2020 Apr; 145(8):3073-3080. PubMed ID: 32142088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
    Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
    Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An electrochemical immunosensor for the prostate specific antigen based on the use of reduced graphene oxide decorated with gold nanoparticles.
    Assari P; Rafati AA; Feizollahi A; Asadpour Joghani R
    Mikrochim Acta; 2019 Jun; 186(7):484. PubMed ID: 31256262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.
    da Silva PB; Real JM; Ferreira LRP; Esteves GH; Brito FDN; Baiocchi OCG
    Hematol Oncol; 2018 Oct; 36(4):709-712. PubMed ID: 30146693
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer.
    Samadi Pakchin P; Fathi M; Ghanbari H; Saber R; Omidi Y
    Biosens Bioelectron; 2020 Apr; 153():112029. PubMed ID: 31989938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
    Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
    Oncogene; 2018 Aug; 37(34):4639-4661. PubMed ID: 29765155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
    Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
    Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.